Can Mid-Cap Lantheus Continue its 2022 Outperformance? Mid-cap Lantheus Holdings has been on a revenue growth spurt boosted by a new product called Pylarify, which helps detect prostate cancer in an imaging test. Previous Article Study Explains if You Should Exercise in the Morning or Evening Next Article Tender Beef Barley Soup
